The Role of Cytotoxic Therapy with Hematopoietic Stem Cell Transplantation in the Treatment of Diffuse Large B Cell Lymphoma: Update of the 2001 Evidence-Based Review

被引：69

作者：

Oliansky, Denise M. ^{[1
]}

Czuczman, Myron ^{[1
]}

Fisher, Richard I. ^{[2
]}

Irwin, Frank D. ^{[3
]}

Lazarus, Hillard M. ^{[4
]}

Omel, James

Vose, Julie ^{[5
]}

Wolff, Steven N. ^{[6
,7
]}

Jones, Roy B. ^{[8
]}

McCarthy, Philip L., Jr. ^{[1
]}

Hahn, Theresa ^{[1
]}

机构：

[1] Roswell Pk Canc Inst, Buffalo, NY 14263 USA

[2] Univ Rochester, James P Wilmot Canc Ctr, Rochester, NY USA

[3] Optum Hlth Care Solut, Minneapolis, MN USA

[4] Case Western Reserve Univ, Case Comprehens Canc Ctr, Univ Hosp Case Med Ctr, Cleveland, OH 44106 USA

[5] Univ Nebraska Med Ctr, Omaha, NE USA

[6] Meharry Med Coll, Nashville, TN 37208 USA

[7] Vanderbilt Univ, Nashville, TN USA

[8] Univ Texas Houston, MD Anderson Canc Ctr, Houston, TX 77030 USA

来源：

BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION | 2011年 / 17卷 / 01期

关键词：

Diffuse large B cell lymphoma; Hematopoietic stem cell transplantation; Systematic evidence-based review; Therapy; Adult; NON-HODGKINS-LYMPHOMA; HIGH-DOSE CHEMOTHERAPY; BONE-MARROW-TRANSPLANTATION; RISK AGGRESSIVE LYMPHOMA; DETUDE DES LYMPHOMES; POOR-RISK; AUTOLOGOUS TRANSPLANTATION; SEQUENTIAL CHEMOTHERAPY; 1ST-LINE TREATMENT; REDUCED-INTENSITY;

D O I：

10.1016/j.bbmt.2010.07.008

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Clinical research published since the 2001 evidence-based review on the role of hematopoietic stem cell transplantation (SCT) in the treatment of diffuse large B cell lymphoma (DLBCL) in adults is presented and critically evaluated in this update. Treatment recommendations that remain unchanged from the original review include: (1) autologous SCT as salvage therapy is recommended for patients with chemosensitive relapsed DLBCL; and (2) autologous SCT is not recommended for patients who achieve a partial response to an abbreviated induction regimen. New treatment recommendations based on new published data include: (1) autologous SCT as first-line therapy is not recommended for any IPI group; (2) planned tandem or multiple sequential autologous SCT is not recommended; (3) peripheral blood is the standard stem cell source for autologous SCT; (4) age is not a contraindication for autologous SCT, although outcomes in older adults are not as good as in younger adults. There are insufficient data to make recommendations on the routine use of rituximab maintenance after autologous SCT, autologous versus allogeneic SCT, fewer versus more cycles of induction therapy prior to autologous SCT, or the use of reduced intensity versus myeloablative conditioning regimens. Areas of needed research in the treatment of DLBCL with SCT were identified and are presented in the review. Biol Blood Marrow Transplant 17: 20-47 (2011) (C) 2011 American Society for Blood and Marrow Transplantation

引用

页码：20 / 47

页数：28

共 82 条

[11] Intensification of salvage treatment with high-dose sequential chemotherapy improves the outcome of patients with refractory or relapsed aggressive non-Hodgkin's lymphoma [J].

Cortelazzo, S ;

Rambaldi, A ;

Rossi, A ;

Oldani, E ;

Ghielmin, M ;

Benedetti, F ;

Tarella, C ;

Zaglio, F ;

Vitolo, U ;

Di Nicola, M ;

Pogliani, E ;

Cavalli, F ;

Gianni, AM ;

Barbui, T .

BRITISH JOURNAL OF HAEMATOLOGY, 2001, 114 (02) :333-341

[12] A phase II trial of rituximab as adjuvant to intensive sequential chemotherapyin patients under 60 years with untreated poor-prognosis diffuse large B-cell lymphoma [J].

Coso, D. ;

Sebban, C. ;

Boulat, O. ;

Biron, P. ;

Rey, J. ;

Aurran, T. ;

Chabannon, C. ;

Xerri, L. ;

Chetaille, B. ;

Esterni, B. ;

Ivanov, V. ;

Stoppa, A. M. ;

de Collela, J. M. Schiano ;

Gastaut, J. A. ;

Maraninchi, D. ;

Bouabdallah, R. .

BONE MARROW TRANSPLANTATION, 2006, 38 (03) :217-222

[13] Impact of intensive PBSC mobilization therapy on outcomes following auto-SCT for non-Hodgkin's lymphoma [J].

Damon, L. ;

Damon, L. E. ;

Gaensler, K. ;

Kaplan, L. ;

Martin, T., III ;

Rubenstein, J. ;

Linker, C. .

BONE MARROW TRANSPLANTATION, 2008, 42 (10) :649-657

[14] Allogeneic haematopoietic stem-cell transplantation for relapsed and refractory aggressive histology non-Hodgkin lymphoma [J].

Doocey, RT ;

Toze, CL ;

Connors, JM ;

Nevill, TJ ;

Gascoyne, RD ;

Barnett, MJ ;

Forrest, DL ;

Hogge, DE ;

Lavoie, JC ;

Nantel, SH ;

Shepherd, JD ;

Sutherland, HJ ;

Voss, NJ ;

Smith, CA ;

Song, KW .

BRITISH JOURNAL OF HAEMATOLOGY, 2005, 131 (02) :223-230

[15] Autologous transplantation for relapsed non-Hodgkin's lymphoma using intravenous busulfan and cyclophosphamide as conditioning regimen: a single center experience [J].

Escalon, M. P. ;

Stefanovic, A. ;

Venkatraman, A. ;

Pereira, D. ;

Santos, E. S. ;

Goodman, M. ;

Byrnes, J. J. ;

Fernandez, H. F. .

BONE MARROW TRANSPLANTATION, 2009, 44 (02) :89-96

[16] Impact of Pre-transplant Rituximab on Survival after Autologous Hematopoietic Stem Cell Transplantation for Diffuse Large B Cell Lymphoma [J].

Fenske, Timothy S. ;

Hari, Parameswaran N. ;

Carreras, Jeanette ;

Zhang, Mei-Jie ;

Kamble, Rammurti T. ;

Bolwell, Brian J. ;

Cairo, Mitchell S. ;

Champlin, Richard E. ;

Chen, Yi-Bin ;

Freytes, Cesar O. ;

Gale, Robert Peter ;

Hale, Gregory A. ;

Ilhan, Osman ;

Khoury, H. Jean ;

Lister, John ;

Maharaj, Dipnarine ;

Marks, David I. ;

Munker, Reinhold ;

Pecora, Andrew L. ;

Rowlings, Philip A. ;

Shea, Thomas C. ;

Stiff, Patrick ;

Wiernik, Peter H. ;

Winter, Jane N. ;

Rizzo, J. Douglas ;

van Besien, Koen ;

Lazarus, Hillard M. ;

Vose, Julie M. .

BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2009, 15 (11) :1455-1464

[17] High-dose chemotherapy and autologous bone marrow transplantation compared with MACOP-B in aggressive B-cell lymphoma [J].

Gianni, AM ;

Bregni, M ;

Siena, S ;

Brambilla, C ;

DiNicola, M ;

Lombardi, F ;

Gandola, L ;

Tarella, C ;

Pileri, A ;

Ravagnani, F ;

Valagussa, P ;

Bonadonna, G ;

Stern, AC ;

Magni, M ;

Caracciolo, D .

NEW ENGLAND JOURNAL OF MEDICINE, 1997, 336 (18) :1290-1297

[18] Shortened first-line high-dose chemotherapy for patients with poor-prognosis aggressive lymphoma [J].

Gisselbrecht, C ;

Lepage, E ;

Molina, T ;

Quesnel, B ;

Fillet, G ;

Lederlin, P ;

Coiffier, B ;

Tilly, H ;

Gabarre, J ;

Guilmin, F ;

Hermine, O ;

Reyes, F .

JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (10) :2472-2479

[19]

GISSELBRECHT C, 2009, J CLIN ONCOL S, V27, pNI376

[20] Dose-escalated CHOP plus etoposide (MegaCHOEP) followed by repeated stem cell transplantation for primary treatment of aggressive high-risk non-Hodgkin lymphoma [J].

Glass, B ;

Kloess, M ;

Bentz, M ;

Schlimok, G ;

Berdel, WE ;

Feller, A ;

Trümper, L ;

Loeffler, M ;

Pfreundschuh, M ;

Schmitz, N .

BLOOD, 2006, 107 (08) :3058-3064

← 1 2 3 4 5 6 7 8 9 →